Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objective response rate and progression-free survival observed in heavily pre-treated patients with platinum-resistant/refractory ovarian cancer. The phase II results also showed that the intra-peritoneal route of delivery was efficient in generating tumor cell killing and immune activation, and led to clinical reversal of platinum-resistance or refractoriness in this difficult-to-treat patient population.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony histologicznie rak jajnika, jajowodu lub osierdzia pierwotnego
- •Wysoko złośliwy typ raka (serous, endometrioid lub jasnokomórkowy)
- •Ogólny stan zdrowia pozwalający na leczenie (ECOG 0-1)
- •Spodziewana długość życia co najmniej 6 miesięcy
- •Co najmniej 3 wcześniejsze leczenia zawierające chemioterapię
- •Rak oporny na platynę (powrót choroby 1-6 miesięcy po ostatniej platynie) lub nieodpowiadający (powrót w ciągu 1 miesiąca)
- •Poprzednie leczenie bevacizumabem
- •Zmierzone zmiany nowotworowe widoczne w badaniach obrazowych i rak w obrębie brzuszenia
✗ Disqualifies
- •Inne typy raka jajnika (śluzowy, niskogradusowy, drobnokomórkowy)
- •Niedrożność jelit w ciągu ostatnich 3 miesięcy
- •Aktywna infekcja układu moczowego, zapalenie płuc lub inne infekcje
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 10, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (32)
The University of South Alabama, Mitchell Cancer Institute
Mobile, United States
University of Arizona Cancer Center
Tucson, United States
City of Hope
Duarte, United States
UC San Diego Health - Moores Cancer Center
La Jolla, United States
Hoag Gynecologic Oncology
Newport Beach, United States
UCI Health Chao Family Comprehensive Cancer Center
Orange, United States
AdventHealth Cancer Institute
Orlando, United States
Sarasota Memorial Healthcare System
Sarasota, United States
Women's Cancer Associates with Women's Care Florida
St. Petersburg, United States
Emory University
Atlanta, United States
Indiana University Simon Comprehensive Cancer Center
Indianapolis, United States
Holy Cross Hospital
Silver Spring, United States
University of Michigan
Ann Arbor, United States
Karmanos Cancer Institute
Detroit, United States
Washington University School of Medicine
St Louis, United States
Mercy Hospital St. Louis
St Louis, United States
Women's Cancer Center of Nevada
Las Vegas, United States
Center of Hope
Reno, United States
Stony Brook Cancer Center
Stony Brook, United States
Levine Cancer Institute
Charlotte, United States
East Carolina University
Greenville, United States
Cleveland Clinic
Cleveland, United States
OhioHealth Research Institute
Columbus, United States
Kettering Health
Kettering, United States
ProMedica Flower Hospital
Sylvania, United States
Oklahoma University Health Stephenson Cancer Center
Oklahoma City, United States
AHN West Penn Hospital
Pittsburgh, United States
Hollings Cancer Center
Charleston, United States
Erlanger Health, Inc.
Chattanooga, United States
Baylor College of Medicine
Houston, United States
University of Texas Science Center at Houston, McGovern Medical School
Houston, United States
Providence Sacred Heart Medical Center & Children's Hospital
Spokane, United States
Trial contact
Stefanie White
Jennifer Pierce, MD
PRINCIPAL_INVESTIGATOR
Mitzi Miranda
Brianna Loughran
Setsuko K. Chambers, MD
PRINCIPAL_INVESTIGATOR
Edward Wang, MD, PhD
Edward Wang, MD, PhD
PRINCIPAL_INVESTIGATOR
Erika Peterson
Michael McHale, MD
PRINCIPAL_INVESTIGATOR
Ramez Eskander, MD
SUB_INVESTIGATOR
Esmeralda Martinez
Alberto Mendivil, MD
PRINCIPAL_INVESTIGATOR
Krishnansu S. Tewari, MD
Krishnansu S. Tewari, MD
PRINCIPAL_INVESTIGATOR
Karla Hernandez-Cruz
Robert W Holloway, MD
PRINCIPAL_INVESTIGATOR
Sarasota Memorial Healthcare System
Beverly Long, MD
PRINCIPAL_INVESTIGATOR
Rebekah Little
Megan Indermaur, MD
PRINCIPAL_INVESTIGATOR
Winship Referrals
Jennifer Scalici, MD
PRINCIPAL_INVESTIGATOR
Cheri West, RN
Jessica E. Parker, MD
PRINCIPAL_INVESTIGATOR
Lyudmila Igorevna Kalnitskaya, MBA, MS
Frederick D Min, MD
PRINCIPAL_INVESTIGATOR
Jasmine Ebott, MD
SUB_INVESTIGATOR
Zhen Zhou
Munira Hussain
Jean Siedel, MD
PRINCIPAL_INVESTIGATOR
Elizabeth Linnik
Robert Morris, MD
PRINCIPAL_INVESTIGATOR
Tiara Redrick
Premal Thaker, MD
PRINCIPAL_INVESTIGATOR
Enguday Teshome
Madhavi Manyam, MD
PRINCIPAL_INVESTIGATOR
Thania Escamilla
Jacky Amador
Nicola M. Spirtos, MD
PRINCIPAL_INVESTIGATOR
Peter Lim, MD
Peter Lim, MD
PRINCIPAL_INVESTIGATOR
Latrice Tribble-Jones
Xavier Geoffroy, MSN, RN
Gabrielle Gossner, MD
PRINCIPAL_INVESTIGATOR
Leah Wilson
Erin K Crane, MD
PRINCIPAL_INVESTIGATOR
Grainger Lanneau, MD
Grainger Lanneau, MD
PRINCIPAL_INVESTIGATOR
Barbara Bittel
Peter Rose, MD
PRINCIPAL_INVESTIGATOR
Jennifer Sexton
Aine Clements, MD
PRINCIPAL_INVESTIGATOR
Daniel Geyer
Thomas J. Reid, MD
PRINCIPAL_INVESTIGATOR
Carissa Jock
Julie Moon
Adam Walter, MD
PRINCIPAL_INVESTIGATOR
Nikolas Williams
Debra Richardson, MD
Debra Richardson, MD
PRINCIPAL_INVESTIGATOR
Sarah Crafton, MD
AHN Clinical Trial
Sarah Crafton, MD
PRINCIPAL_INVESTIGATOR
Crystal Knox
Brian Orr, MD
PRINCIPAL_INVESTIGATOR
Lorraine Christensen
Kimberly Donelson
Stephen DePasquale, MD
PRINCIPAL_INVESTIGATOR
Jan Sunde, MD
Jan Sunde, MD
PRINCIPAL_INVESTIGATOR
Gabrielle Hayes
Joseph Lucci, III, MD
PRINCIPAL_INVESTIGATOR
Jodie Mactagone, CRC
Melanie Bergman, MD
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/11/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.